Sanford Burnham Prebys Medical Discovery Institute

Sanford Burnham Prebys to develop broad-spectrum antivirals with $10 million Department of Defense grant

Sumit Chanda will lead global collaboration to develop drugs that protect against multiple respiratory viruses

Newswise — Sanford Burnham Prebys Medical Discovery Institute is pleased to announce that Sumit Chanda, Ph.D., has received a $10.2 million, four-year grant from the Department of Defense to develop and advance broad-spectrum antivirals for respiratory diseases. The award aims to provide U.S. military forces and the nation with safe, effective and innovative therapies that combat multiple types of respiratory viruses. 

“We want to move away from the ‘one-bug-one-drug’ paradigm and develop drug candidates that are effective against multiple respiratory viruses,” says Chanda, director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys. “While respiratory diseases caused by bacteria are relatively simple to treat with broad-spectrum antibiotics, we don’t have the same type of medications available for viral respiratory infections. Broad-spectrum respiratory antiviral drugs could greatly benefit military personnel in settings where point-of-care diagnostics are not available, as well as when a virus seemingly comes out of nowhere, like SARS-CoV-2 did.” 

Most antiviral drugs selectively target a single virus, providing a “one-bug-one-drug” solution. In contrast, bacterial infections are often treated with broad-spectrum antibiotics that can not only be used against a wide variety of bacteria but also against infections where the type of bacteria has yet to be identified. The availability of broad-spectrum respiratory antivirals would enable military personnel to be treated early, prior to a diagnosis, thereby reducing the likelihood of secondary infections and spread throughout closely housed military quarters. 

“Our strategy to develop broad-spectrum respiratory antivirals is to target host (human) proteins, rather than current strategies that target viral proteins,” Chanda explains. “This is necessary because viruses are profoundly different from bacteria— in order to survive, they hijack our cellular machinery to make millions of copies of themselves. If we can protect the features in our cells that viruses depend on for their life cycle, we can prevent their replication and spread. Since different respiratory viruses take advantage of the same host functions, one drug could be effective against many viruses.” 

Respiratory viruses are the most commonly diagnosed medical conditions among military recruits and trainees. During 2005 and 2006 in Iraq and Afghanistan, deployed military experienced respiratory illness at a rate of approximately 15% per month, with overall rates at approximately 40% of all personnel. These infections can significantly impact training and readiness, putting the nation at risk. 

The research team currently has four preclinical drug-like small molecules that exhibit broad-spectrum activity. Their goal is to advance at least two antivirals upon the completion of the project that can be quickly transitioned to the clinic. They are currently focused on evaluating if these molecules can by optimized and deployed to address the current SARS-CoV-2 pandemic. 

“We anticipate that these respiratory antivirals could treat infections caused by viruses including influenza A and B, human rhinoviruses, respiratory syncytial virus, adenoviruses—and importantly—coronaviruses,” says Adolfo García-Sastre, Ph.D., professor in the Department of Microbiology and co-director of the Global Health & Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai, and collaborator on the project. “Our collective experience in researching the molecular biology of viruses will lead to new approaches to combat deadly respiratory viruses that affect millions of people and lay the groundwork for protecting us against viruses yet unknown.” 

In addition to García-Sastre, collaborators on the project include Michael Gale Jr., Ph.D. (University of Washington), Megan Shaw, Ph.D. (University of the Western Cape, South Africa), Hong Moulton, Ph.D. (Oregon State University), and Michael Bollong, Ph.D. (Scripps Research).




About Sanford Burnham Prebys Medical Research Institute 

Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 40 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children’s diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us at or on Facebook at and on Twitter @SBPdiscovery.



Filters close

Showing results

110 of 3821
Newswise: UC Davis Health announces Post-COVID-19 Clinic for long-haul patients
Released: 28-Oct-2020 5:20 PM EDT
UC Davis Health announces Post-COVID-19 Clinic for long-haul patients
UC Davis Health

UC Davis Health is one of only a handful of health systems in the U.S. to launch a Post-COVID-19 Clinic to care for long-haul COVID patients whose symptoms go on and on, sometimes for months, with no clear explanation or avenue for treatment.

Newswise: Most People Mount a Strong Antibody Response to 
SARS-CoV-2 That Does Not Decline Rapidly
Released: 28-Oct-2020 5:20 PM EDT
Most People Mount a Strong Antibody Response to SARS-CoV-2 That Does Not Decline Rapidly
Mount Sinai Health System

The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 28, in the journal Science.

Newswise: 45a1c2a0-c0a4-11ea-b53e-cb3f2ed770b1.jpg
Released: 28-Oct-2020 4:00 PM EDT
Investigator on the AtraZeneca vaccine trial will take questions at Live Event on Oct. 29, 3PM
Keck Medicine of USC

Dr. Edward Jones-Lopez, joins a Newswise Live Expert Panel on Thursday Oct. 29, from 3-4 PM EDT to discuss the AstraZenea COVID-19 vaccine trial.

Released: 28-Oct-2020 4:00 PM EDT
"Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29, 3PM EDT

"Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29, 3PM EDT

Newswise: Oak Ridge National Laboratory industry collaboration enables job growth, N95 mask production in Florida
Released: 28-Oct-2020 2:15 PM EDT
Oak Ridge National Laboratory industry collaboration enables job growth, N95 mask production in Florida
Oak Ridge National Laboratory

A collaboration between the Department of Energy’s Oak Ridge National Laboratory and a Florida-based medical device manufacturer has led to the addition of 500 jobs in the Miami area to support the mass production of N95 respirator masks.

Released: 28-Oct-2020 1:55 PM EDT
What EEGs tell us about COVID-19 and the brain
Baylor College of Medicine

Throughout the pandemic, healthcare workers have seen more than just the lungs affected by COVID-19. Doctors have reported neurological complications including stroke, headache and seizures, but the information is limited to a number of individual reports that are not reflective of a larger population.

Released: 28-Oct-2020 1:50 PM EDT
A new playbook: COVID-19, athletes' hearts and return to play
Massachusetts General Hospital

Reports have indicated that COVID-19 may cause heart damage in hospitalized patients with severe cases of the disease, but it's unclear whether cardiac injury also occurs in infected patients who are asymptomatic or experience only mild symptoms.

Newswise: 0815UCI20052-1069-768x512.jpg
Released: 28-Oct-2020 1:05 PM EDT
Antibody screening finds COVID-19 nearly 7 times more prevalent in O.C. than thought
University of California, Irvine

Irvine, Calif., Oct. 28, 2020 — Testing a representative sample of Orange County residents for a wide range of coronavirus antibodies, University of California, Irvine researchers found that 11.5 percent of them have antibodies for COVID-19, in contrast to previous estimates of less than 2 percent. Latino and low-income residents had the highest prevalence of SARS-CoV-02 antibodies with rates of 17 percent and 15 percent, respectively.

Released: 28-Oct-2020 1:05 PM EDT
Researchers find confusion over masks for wildfire, COVID-19 crises
Stanford School of Earth, Energy & Environmental Sciences

To mask or not to mask - and which mask to use? With public health guidance about masks in the United States confused by political hedging, clarity around mask use is increasingly important, especially as the western U.S. battles the twin crises of wildfire smoke and COVID-19.

Showing results

110 of 3821